1832 Asset Management’s Axsome Therapeutics AXSM Stock Holding History

1832 Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.3M	Buy	143,800 +130,100	+950%	+$22.5M	0.02%	285
2025 Q4	$2.5M	Buy	+13,700	New	+$1.91M	﹤0.01%	500
2025 Q2	–	Sell	-363,200	Closed	-$42.4M	–	665
2025 Q1	$42.4M	Buy	+363,200	New	+$41.4M	0.04%	216
2023 Q1	–	Sell	-118,200	Closed	-$9.12M	–	889
2022 Q4	$9.12M	Buy	+118,200	New	+$7.07M	0.02%	356

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

1832 Asset Management's AXSM Position: Q1 2026 in Review

1832 Asset Management increased its Axsome Therapeutics (AXSM) stake by 950% in Q1 2026, buying an estimated $22.5M and bringing the position to 143,800 shares worth $24.3M. The position accounts for 0.02% of the portfolio, ranked #285.

1832 Asset Management first reported a position in AXSM in Q4 2022 and has held it in 4 quarters since. The position peaked at $42.4M in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

1832 Asset Management held 143,800 shares of Axsome Therapeutics worth $24.3M as of Q1 2026.
1832 Asset Management bought 130,100 Axsome Therapeutics shares in Q1 2026, an estimated $22.5M.
Axsome Therapeutics made up 0.02% of 1832 Asset Management's portfolio in Q1 2026, its #285 holding.
1832 Asset Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 4 quarters since.
1832 Asset Management's Axsome Therapeutics position peaked at $42.4M in Q1 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.